FIELD MEDICAL CLOSES $40 MILLION SERIES A FINANCING TO REDEFINE PULSED FIELD ABLATION FOR VENTRICULAR TACHYCARDIA

Field Medical, Inc. Vermont California

and follow us on LinkedIn and X.

The FieldForce™ Ablation System is an investigational device and is limited by federal (or United States) law to investigational use.

The Growing Prevalence of VT and AF
Ventricular tachycardia (VT) and atrial fibrillation (AF) are two of the most common and serious arrhythmias, contributing to stroke, heart failure, sudden cardiac death and escalating health care costs. VT and premature ventricular contractions (PVCs) affect more than 6 million people in the United States and Europe, while AF impacts an estimated 2% to 6% of the global population.

The AF catheter ablation market is currently valued at $5 billion and is projected to grow at a compound annual growth rate of 13% to 16%, surpassing $11 billion by 2034. In comparison, the global VT market— which includes devices and catheter ablation—was valued at approximately $12.5 billion in 2021 and is expected to grow at a compound annual growth rate of 5.26%, reaching $17 billion by 2027. Notably, the catheter ablation segment within the VT treatment market is projected to grow at a higher rate of 13% annually during this period, reflecting increased adoption of catheter-based interventions for VT management.

Media Contact
Holly Windler
619.929.1275

Logo - https://mma.prnewswire.com/media/2574173/Field_Medical_Logo_Block_WhiteOnBlack_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/field-medical-closes-40-million-series-a-financing-to-redefine-pulsed-field-ablation-for-ventricular-tachycardia-302433815.html